Pack size: Box of 120 Capsules  |  Price is for the whole Box

⚠ Prescription required. This medicine may only be dispensed against a valid prescription.

Generic: Alectinib

Form: Capsule 150mg

Indication

Non-small Cell Lung Cancer, Indicated for anaplastic lymphoma kinase (ALK)-positive, metastatic non-small cell lung cancer (NSCLC) ALK-positive, locally advanced or metastatic NSCLC who have progressed on or are intolerant to crizotinib.

Administration

Should be taken with food: Swallow whole, do not open/dissolve the cap.

Adult Dose

Non-small Cell Lung Cancer 600 mg PO BID until disease progression or unacceptable toxicity Dose reduction schedule Starting dose: 600 mg PO BID First dose reduction: 450 mg PO BID Second dose reduction: 300 mg PO BID Discontinue if patients are unable to tolerate 300 mg PO BID Nephrotoxicity Grade 3: Temporarily withhold until serum creatinine recovers to ?1.5x ULN, then resume at reduced dose Grade 4: Permanently discontinue Hepatotoxicity ALT or AST elevation >5x ULN with total bilirubin (TB) ?2x ULN: Temporarily withhold until recovery to baseline or to ?3 times ULN, then resume at reduced dose ALT or AST elevation >3x ULN with TB elevation >2x ULN in absence of cholestasis or hemolysis: Permanently discontinue TB elevation >3x ULN: Temporarily withhold until recovery to baseline or to ?1.5x ULN, then resume at reduced dose Hepatic impairment Mild (TB ?ULN and AST >ULN or TB >1-1.5x ULN and any AST): No dose adjustment required Moderate-to-severe: Not studied

Renal Dose

Renal impairment Mild-to-moderate: No dose adjustment required Severe (CrCl <30 mL/min) or ESRD: Not studied

Contraindication

Hypersensitivity.

Mode of Action

Tyrosine kinase inhibitor that targets ALK and RET In nonclinical studies, alectinib inhibited ALK phosphorylation and ALK-mediated activation of the downstream signaling proteins STAT3 and AKT, and decreased tumor cell viability in multiple cell lines harboring ALK fusions, amplifications, or activating mutations The major active metabolite of alectinib, M4, showed similar in vitro potency and activity Alectinib and M4 demonstrated in vitro and in vivo activity against multiple mutant forms of the ALK enzyme, including some mutations identified in NSCLC tumors in patients who have progressed on crizotinib